You are here

Accurate Early Detection of Preeclampsia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 1R43HD039975-01A2
Amount: $99,998.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1316 WOODLAND AVE
JOHNSON CITY, TN 37601
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BRADLEY ARBOGAST
 () -
Business Contact
Phone: (423) 929-1974
Email: BARBOGAST@CSI.COM
Research Institution
N/A
Abstract

Use of a new noninvasive test for the accurate early detection of preeclampsia is proposed as a tool to screen women during early stages of pregnancy. Preeclampsia affects 10% of the 4 million pregnancies in the U.S. each year and is the leading cause of maternal and neonatal medical complications and death. There is currently no means of detecting preeclampsia prior to onset of clinical symptoms in the third trimester. Preliminary results using an isoelectric focusing (IEF) assay demonstrated that levels of a subfraction of serum albumin could be used to accurately predict the onset of disease months prior to the appearance of symptoms. A new colorimetric test has the potential to provide the same screening accuracy without the cumbersome equipment or time consuming procedures of the IEF method. Analysis times employing a routine blood sample average 2 hours. Five hundred individual samples can easily be processed in half a day by a single laboratory technician. We propose to validate the accuracy and optimize the conditions of this new assay using frozen plasma samples collected from carefully monitored patient populations at several major medical centers. We believe this assay will revolutionize the area of maternal medicine. PROPOSED COMMERCIAL APPLICATIONS: The need for an early detection of preeclampsia is well established. The market potential for a test that could rapidly and accurately screen the yearly 4 million pregnancies at low cost would be sizable. Repetitive testing to monitor the progress throughout the pregnancy of women identified in the initial screen as preeclamptic would provide an additional market for this product. This test could also be used in research laboratories to detect early changes in maternal physiology leading to improved treatment and prevention of this disease.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government